MEK Inhibitor Adds No Value in Treatment of KRAS-Mutant NSCLC

Adding selumetinib to docetaxel does not provide any significant benefit over docetaxel alone for patients previously treated for advanced KRAS-mutant non –small-cell lung cancer.

Source: CancerNetwork - May 9, 2017 Category: Cancer & Oncology Authors: Mark L. Fuerst Tags: Lung Cancer News Source Type: news